News

The cobas e 602 module, which uses Roche’s patented electrochemiluminescence (ECL) technology, includes more than 50 assays on its initial test menu and offers a throughput of up

Novartis said that the agreement is an extension to the existing relationship with Adesso Solutions and confirms they will continue to provide trade planning and execution, check request

In the trial, the improvement in FEV1, the primary endpoint, was prominent in the 200ug (p=0.019) and 400ug (p=0.001) BID dose groups. However, for the expected therapeutic dose,

Degarelix is a gonadtrophin-releasing hormone (GnRH) blocker with a subcutaneously injectable formulation. In January 2006, Astellas and Ferring International Center entered into a license agreement that gives Astellas

In its CRL, the FDA has informed Vivus that the NDA for Qnexa cannot be approved in its present form. The CRL included the following areas: clinical, labeling,

Following the establishment of the Hangzhou Sanofi Minsheng Consumer Healthcare joint venture, the acquisition of BMP Sunstone will make sanofi-aventis a consumer healthcare company in China, with a

Bristol-Myers Squibb and Otsuka Pharmaceutical are collaborative partners in the commercialisation of Sprycel in the US, Japan and major European countries. Sprycel was discovered and developed by Bristol-Myers

Humira, a fully human anti-TNF monoclonal antibody that exerts its effects by neutralising TNF, is a cytokine that plays a central role in inflammatory responses. Humira is already

The Multi-Source Injectables business comprises a portfolio of 41 products in over 150 dosage strengths and forms across 23 therapeutic areas. The business’ product portfolio also includes several